Astellas Pharma US, Inc.
=
Northbrook
Illinois
60062
United States
637 articles with Astellas Pharma US, Inc.
-
With this new collaboration, Astellas will take advantage of Dynos' next-gen AAV vectors to deliver its gene therapy.
-
Astellas to Present Research on FLT3 Mutation-Positive Acute Myeloid Leukemia - from Diagnosis to Relapse - at 2021 American Society of Hematology Annual Meeting
12/1/2021
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the presentation of new investigational data in acute myeloid leukemia (AML) and sickle cell disease at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 11-14, in Atlanta, Ga.
-
Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle
12/1/2021
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Dyno Therapeutics, Inc. (President and CEO: Eric Kelsic, Ph.D., "Dyno") today announced an option and license agreement was signed on November 23 to develop next-generation adeno-associated virus (AAV) vectors for gene therapy directed to skeletal and cardiac muscle using Dyno's CapsidMap™ platform.
-
Five months after the company launched, Acrivon Therapeutics secured $100 million in Series B financing to support the clinical development of a cancer asset it licensed from Eli Lilly.
-
Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) with Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
10/12/2021
Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq:SGEN) today announced that patient enrollment was completed in Cohort K of the phase 1b/2 EV-103 clinical trial (also known as KEYNOTE-869).
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Japan's MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
9/27/2021
Astellas Pharma Inc. and Seagen Inc. announced that Japan's Ministry of Health, Labour and Welfare has approved PADCEV® for radically unresectable urothelial carcinoma that has progressed after anti-cancer chemotherapy.
-
Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer (mCRPC) Study
9/21/2021
Zenith Epigenetics Ltd. and Newsoara BioPharma Co., Ltd. announced the initiation of a multi-national, randomized Phase 2b clinical trial testing the combination of ZEN-3694, a leading BET bromodomain inhibitor, with Astellas Pharma Inc. and Pfizer’s androgen receptor signaling inhibitor, enzalutamide, in patients with mCRPC who had a poor response to prior abiraterone treatment.
-
Clinical Catch-Up: September 13-17
9/20/2021
With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look. -
Astellas' and Pfizer's XTANDI® (enzalutamide) Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 ARCHES Study
9/17/2021
Astellas Pharma Inc. and Pfizer Inc. announced ahead of the European Society for Medical Oncology Congress 2021 that XTANDI® improved overall survival in the ARCHES study in men with metastatic hormone-sensitive prostate cancer.
-
Astellas Reports Update to September 1 Announcement on the ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy
9/14/2021
Astellas Pharma Inc. reports that the ASPIRO clinical trial participant, who developed a serious adverse event as described on September 1, passed away on September 9.
-
A patient treated with Astellas Pharma’s experimental gene therapy for patients with X-linked Myotubular Myopathy (XLMTM) has died after a serious adverse event following treatment.
-
There were a fair number of clinical trial announcements last week. Here’s a look.
-
Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy
9/1/2021
Astellas Pharma Inc. announced that it has voluntarily paused screening and dosing of additional participants in its ASPIRO clinical trial evaluating AT132 in patients with X-linked Myotubular Myopathy.
-
The company announced it paused the screening and dosing of an investigational gene therapy for patients with XLMTM following a serious adverse event report in a trial participant.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
The U.S. FDA had a very packed calendar for this week, but almost everything on it was under a Priority Review pathway.
-
Astellas and Minovia Therapeutics Announce Strategic Collaboration for Novel Mitochondrial Cell Therapy Programs
7/30/2021
Minovia Therapeutics, Ltd. (CEO; Natalie Yivgi-Ohana, Ph.D., “Minovia”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced a worldwide strategic collaboration and license agreement for the research, development, and commercialization of novel cell therapy programs for diseases caused by mitochondrial dysfunction.
-
Astellas Pharma is building on a 2019 collaborative relationship and snapping up California-based iota Biosciences and that company’s bioelectronics technology in order to accelerate its Rx+ business.
-
Clinical Catch-Up: June 8-12
6/15/2020
It was a fairly busy week with clinical trial updates and announcements. Here’s a look.